Arrowhead Research Corporation (ARWR) Receives Price Target

Arrowhead Research Corporation (ARWR) : The highest level Arrowhead Research Corporation (ARWR) is projected to reach is $15 for the short term and the lowest estimate is at $6. The consolidated price target from 6 rating analysts who initiate coverage on the stock is $10.42 and the possibility the share price can swing is $3.85.


Also, Cantor Fitzgerald initiates coverage on Arrowhead Research Corporation (NASDAQ:ARWR). The rating major has initiated the coverage with buy rating on the shares. The rating by the firm was issued on August 18, 2016.

Arrowhead Research Corporation (NASDAQ:ARWR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $6.85 and $6.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.06, notching a gain of 1.88% for the day. The total traded volume was 465,702 . The stock had closed at $6.93 on the previous day.

Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Companys therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Companys drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.